Stevanato Group Launches Deora Pen Injector for Diabetes and Weight Management Therapies
Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions for the pharmaceutical, biotechnology, and life sciences industries, recently introduced Deora, a new proprietary pen injector platform targeting incretin-based therapies, as well as supporting other originator and biosimilar drug development programs. Deora is a multi-use, fixed-dose pen injector featuring […]
Samsung Bioepis Partners with NIPRO to Commercialize Biosimilars in Japan
Samsung Bioepis Co., Ltd., on June 8th, announced that the company has entered into a license, development and commercialisation agreement with NIPRO Corporation for multiple biosimilar candidates, including SB17, an ustekinumab biosimilar candidate, in Japan. Under the terms of the agreement, Samsung Bioepis will be responsible for the development, manufacture and supply of the medicines, […]